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Abstract
Introduction Axial spondyloarthropathy (SpA) is a group of
inflammatory diseases, with ankylosing spondylitis as the
prototype. SpA affects the axial skeleton, entheses, joints and,
at times, the eyes. This study tested the hypothesis that SpA is
characterized by a distinct pattern of gene expression in
peripheral blood of affected individuals compared with healthy
controls.
Methods High-density, human GeneChip® probe arrays were
used to profile mRNA of peripheral blood cells from 18 subjects
with SpA and 25 normal individuals. Samples were processed
as two separate sets at different times (11 SpA + 12 control
subjects in primary set (Set 1); 7 SpA+ 13 control subjects in
the validation set (Set 2)). Blood samples were taken at a time
when patients were not receiving systemic immunomodulatory
therapy. Differential expression was defined as a 1.5-fold
change with a q value < 5%. Gene ontology and pathway
information were also studied.
Results Signals from 134 probe sets (representing 95 known
and 12 unknown gene transcripts) were consistently different
from controls in both Sets 1 and 2. Included among these were
transcripts for a group of 20 genes, such as interleukin-1 (IL-1)
receptors 1 and 2, Nod-like receptor family, pyrin domain
containing 2 (NLRP2), secretory leukocyte peptidase inhibitor
(SLPI), secreted protein acidic and rich in cysteine (SPARC),
and triggering receptor expressed on myeloid cells 1 (TREM-1)
that are clearly related to the immune or inflammatory response
and a group of 4 transcripts that have a strong role in bone
remodeling.
Conclusions Our observations are the first to implicate SPARC,
SLPI, and NLRP2, a component of the innate immune system, in
the pathogenesis of SpA. Our results also indicate a possible
role for IL-1 and its receptors in SpA. In accord with the bone
pathology component of SpA, we also found that expression
levels of transcripts reflecting bone remodeling factors are also
distinguishable in peripheral blood from patients with SpA
versus controls. These results confirm some previously
identified biomarkers implicated in the pathogenesis of SpA and
also point to novel mediators in this disease.
BMP: bone morphogenetic protein; CEL: cell fluorescence intensity; DKK-1: Dickkopf-1; GCOS: GeneChip Operating System; GC-RMA: GC 
Robust Multiarray Analysis; IL-1: interleukin-1; IL-1R: interleukin-1 receptor; NLRP2 (NALP2): Nod-Like Receptor family, pyrin domain containing 2; 
OHSU: Oregon Health & Science University; PM: perfect match; SAM: Significance Analysis of Microarrays; SLPI: secretory leukocyte peptidase 
inhibitor; SpA: axial spondyloarthropathy; SPARC: secreted protein acidic and rich in cysteine (also known as osteonectin); TNF: tumor necrosis fac-
tor; TREM-1: triggering receptor expressed on myeloid cells 1.Arthritis Research & Therapy    Vol 11 No 6    Sharma et al.
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Introduction
Axial spondyloarthropathy (SpA) is a family of polygenic inflam-
matory diseases for which the pathophysiology is complex,
with much remaining unknown. Ankylosing spondylitis is the
most common form of SpA. Study of gene expression using
microarrays offers a novel approach to determining pathogen-
esis of diseases. Analysis of peripheral blood in patients with
systemic lupus erythematosus using this technique has led to
the discovery that many lupus patients have an upregulation of
genes induced by type I interferons [1].
The present study utilizes a methodology that incorporates an
experimental design consisting of primary and validation data-
sets of subjects, a comprehensive microarray platform, and
robust statistical techniques to investigate the presence of a




This study is in compliance with the Helsinki Declaration and
was approved by the Oregon Health & Science University
(OHSU) Institutional Review Board. Patients with SpA attend-
ing the Uveitis or Rheumatology Clinics at OHSU were
recruited to this study and informed consent was obtained
before samples were collected. SpA was diagnosed based on
the calculation of a likelihood score, as described by Rud-
waleit and colleagues [2]. A diagnosis of SpA is made if the
likelihood ratio product for all positive factors exceeds 200
[3,4]. Because patients were attending an eye disease clinic,
joint disease activity was not formally assessed. However, the
likelihood ratio indicates a 90% probability that the subjects
have SpA. Ulcerative colitis in one patient was permitted in the
SpA group because it is known that SpA may co-exist with
inflammatory bowel disease [4]. One patient had psoriasis. All
other autoimmune diseases were excluded. Chronic systemic
conditions were allowed, as were medications for co-existent
morbidities. Systemic immunomodulatory therapy was not per-
mitted. Only one patient is known to have received a TNF
inhibitor (etanercept), and this had been discontinued two
months prior to the blood draw for this study.
Gene expression in these subjects was compared with that in
25 healthy control subjects without a history of autoimmune
disease. Tables 1, 2 and 3 contain demographic and clinical
information for the SpA and healthy control subjects. Male
subjects in the SpA group outnumbered females as is charac-
teristic of this disease. Neither SpA nor control subjects were
on oral corticosteroids or other immunomodulatory therapy.
Samples were processed and the results analyzed as two sep-
arate datasets, a primary set and validation set, at two different
times.
Gene expression microarray
Unfractionated whole blood collection and RNA isolation were
performed using the PAXgene Blood RNA Isolation System
(PreAnalytiX, a Qiagen BD Company, Valencia, CA, USA)
according to the manufacturer's recommendation. Microarray
assays were performed in the Affymetrix Microarray Core, a
unit of the OHSU Gene Microarray Shared Resource. Total
RNA was amplified and labeled using a one-cycle target-labe-
ling method modified to reduce globin mRNA targets (Gene-
Chip Globin Reduction Protocol rev.1; Affymetrix, Inc., Santa
Clara, CA, USA) and hybridized according to the manufac-
turer. The high density, human GeneChip® probe arrays (HG-
U133 Plus 2.0, Affymetrix, Inc, Santa Clara, CA, USA) were
used. Each array contains 54,000 probe sets designed to ana-
lyze the expression of 47,000 human transcripts and variants.
Hybridized arrays were processed using the Fluidics Station
450 (Affymetrix, Inc, Santa Clara, CA, USA) and distribution of
fluorescence was measured using the Gene Chip Scanner
3000 (Affymetrix, Inc, Santa Clara, CA, USA). Cell fluores-
cence intensity (CEL) files were generated using the Gene
Chip Operating System (GCOS) software version 1.2
(Affymetrix, Inc, Santa Clara, CA, USA).
Statistical analysis
The 'affy' and 'gcrma' packages of Bioconductor [5] were
used to preprocess and normalize the data following import of
CEL files into the R statistical package (Affymetrix, Inc, Santa
Clara, CA, USA). The GC Robust Multiarray Analysis (GC-
RMA) was used to adjust perfect match (PM) probe data for
background noise [6]. Normalization was performed on
adjusted PM data with an algorithm based on rank invariant
Table 1
Dataset characteristics
Dataset 1 Dataset 2 Combined sets
SpA Control SpA Control SpA Control
Age (mean ± SD) 51.8 ± 12.8 48.8 ± 21.4 46.7 ± 14.5 35.4 ± 9.7 49.7 ± 12.9 41.8 ± 17.4
Years since SpA diagnosis (mean ± SD) 16.2 ± 14.9 8.2 ± 11.2 13.7 ± 14.0
Males/females 9/2 4/8 4/3 1/12 13/5 5/20
The age and disease duration data have been summarized to protect subject privacy. SD = standard deviation; SpA = axial spondyloarthropathy.Available online http://arthritis-research.com/content/11/6/R168
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probes [7]. After normalization, differential gene expression
between groups was assessed by Significance Analysis of
Microarrays (SAM) [8]. Differential expression was defined as
a 1.5-fold change with a q value less than 5%. The q value is
a Bayesian equivalent to the false discovery rate adjusted P
value [9]. Statistical analysis was performed at an array probe
set level; transcript counts were corrected for the presence of
multiple probe sets. These data have been used to illustrate an
analytical approach described in a statistical methods paper
[10] and the controls were also used in a parallel study on
gene expression in patients with sarcoidosis [11]. The raw and
normalized data have been deposited in the Gene Expression
Omnibus repository [GEO: GSE18781] [12].
As males predominated among the SpA subjects and females
were more common in the control group, we took additional
caution to exclude conclusions attributable to gender. To iden-
tify possible gender effects on gene expression levels that
might confound interpretation of the intergroup comparisons,
an analysis was conducted to determine which of the following
four linear models best fit the data for each probe set: (1) a
model in which gene expression is impacted by disease state
alone; (2) a model in which gender is the sole influence on
gene expression; (3) a model in which, after controlling for
gender effects, the principal effects are due to disease state;
and (4) a model in which the interaction between disease state
and gender also influences the results. For this analysis, data
from both sets were first renormalized using the quantile nor-
malization method [13]. The well-established Akaike's informa-
tion criterion [14] was then used to choose the best among
four models for each probe set shown in Tables 4 and 5 based
on likelihood calculations.
Pathway analysis of gene expression results
Each gene was studied using a network analysis module
within MetaCore™ bioinformatics software (GeneGo Inc, St.
Joseph, MI, USA) [15] to identify known functional associa-
tions between genes identified in our study and other genes or
pathways. These curated networks may include transcription
factors, receptors, and enzyme cascades.
Results
Gene expression microarray analysis was performed on whole
blood collected from two independent sets of SpA and control
subjects. Our analysis of Set 1 identified 556 probe sets that
were upregulated and 962 probe sets that were downregu-
Table 2
Individual SpA subject characteristics
Subject Dataset Gender Race SpA Likelihood ratio Medications
1 1 M Asian 4073 None (Etanercept withdrawn for 2 months)
2* 1 M Caucasian 204 Simvastatin, cyclobenzaprine, aspirin, indomethacin, atenolol, lansoprazole, 
hydrocodone
3 1 M Caucasian 204 _
4 1 M Caucasian 4073 _
5 1 M Caucasian 934 _
61M A s i a n 2 0 4 _
7 1 M Caucasian 4073 Metformin, glipizide, atorvastatin, lisinopril, nifedipine, Lantus insulin, Novo 
Log, sulfasalazine, indomethacin
8 1 M Caucasian 558 Ibuprofen
9 1 F Caucasian 11383 Piroxicam, indomethacin
10 1 F Caucasian 7115 Rofecoxib
11 1 M Caucasian 255 Acetaminophen, ramipril, omeprazole, aspirin, atorvastatin
12 2 M Caucasian 4073 Insulin, nifedipine, glipizide, lisinopril, metformin, Vicodin, Flexeril, 
indomethacin, sulfasalazine
13 2 F Caucasian 1039 Celecoxib, trazodone, venlafaxine, ranitidine
14 2 F Caucasian 204 Tobramycin
15 2 F Asian 4073 Alendronate
16 2 M Asian 204 _
17 2 M Caucasian 20774 Phenylbutazone
18 2 M Caucasian 2308 Alendronate sodium
*coexistent ulcerative colitis. F = female; M = male; SpA = axial spondyloarthropathy.Arthritis Research & Therapy    Vol 11 No 6    Sharma et al.
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lated in subjects with SpA compared with healthy control sub-
jects. Because some transcript levels were evaluated by
multiple probe sets on the microarray chip, the chosen probe
sets corresponded to 369 upregulated gene transcripts and
721 downregulated gene transcripts. In Set 2, 704 probe sets
(550 gene transcripts) were upregulated; 14 probe sets (7
gene transcripts) were downregulated in patients with SpA
relative to the control subjects. Heat maps illustrate differ-
ences between the groups [see Additional data file 1]. There
were 124 probe sets (92 known and 10 unidentified gene
transcripts) that were classified in both sets as upregulated in
SpA subjects; 10 probe sets (3 known and 2 unidentified
gene transcripts) were downregulated in both sets [see Addi-
tional data file 2].
We conducted a literature search using National Center for
Biotechnology Information databases, including PubMed [16],
on all significantly over- or underexpressed gene transcripts to
determine their biological functions. Within the group of tran-
scripts identified in both sets, there were 20 gene transcripts
involved in immunity or inflammation that might constitute part
of the immune signature in SpA. Table 4 presents these tran-
scripts with functional annotations. In particular, we found
upregulation of IL-1 receptors and the downregulation of a
potential regulator of the IL-1 pathway, NLRP2. Other upregu-
lated transcripts of interest included 'secreted protein acidic
and rich in cysteine' (SPARC) and secretory leukocyte pepti-
dase inhibitor (SLPI). Four gene transcripts that have a role in
bone remodeling, including kremen 1, were differentially
Table 3
Individual control subject characteristics
Subject Data-set Gender Race Medications
19 1 F Caucasian Alphagan OP, Xalatan OP
20 1 F Caucasian _
21 1 F Caucasian Atorvastatin, losartan, atenolol, aspirin, hydrochlorothiazide
22 1 M Caucasian Atorvastatin, glargine, lisinopril, fluoxetine, amlodipine, Systane OP
23 1 F Caucasian Levothyroxine, sertraline
24 1 M Caucasian Diazepam, simvastatin, aspirin
25 1 M Caucasian Ibuprofen
26 1 F Caucasian _
27 1 F Caucasian Sertraline, desogestrel/ethinyl estradiol
28 1 M Caucasian Ibuprofen, diazepam, acetaminophen/aspirin, esomeprazole, sumatriptan
29 1 F Caucasian _
30 1 F Asian Trazodone, sertraline, levonorgestrel/ethinyl, estradiol, atorvastatin, ibuprofen, acetaminophen
31 2 F Caucasian Acetaminophen, ibuprofen
32 2 F Caucasian _
33 2 F Mixed* _
34 2 F Caucasian Ibuprofen
35 2 F Caucasian Etonogestrel/ethinyl estradiol VA
36 2 F Caucasian _
37 2 F Caucasian Etonogestrel/ethinyl estradiol VA, cetirizine
38 2 F Caucasian Desogestrel/ethinyl estradiol
39 2 F Caucasian _
40 2 F Caucasian Estradiol 0.01% cream, levonorgestrel
41 2 M Caucasian _
42 2 F Caucasian Duloxetine, valacyclovir, cyclobenzaprine
43 2 F Caucasian _
*mixed race is seven out of eight Caucasian and one out of eight African-American.Available online http://arthritis-research.com/content/11/6/R168
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expressed (Table 5). These might form part of a bone remod-
eling signature for SpA.
Because of a disproportionate number of females in the con-
trol group, we conducted a post hoc analysis of variance on
the effect of gender. Four models based on different effects of
gender and disease state on gene expression were consid-
ered. Akaike's information criterion was used to select the
model that best fits the data for each probe set. For 14 of the
24 genes included in this secondary analysis, Akaike's infor-
mation criterion selected the model that assigned the principle
expression differences to the disease state after correcting for
a gender effect (model 3 in the methods section). The model
selected for the remaining 10 genes (marked with an asterisk
in Tables 4 and 5) also included an interaction effect of dis-
ease state and gender (model 4). For these genes, male sub-
jects with SpA had higher fold-changes than both control
subjects and female subjects with SpA, and we cannot
Table 4
Putative immune signature in SpA
Set 1 Set 2
Gene symbol Gene name Fold change Q (%) Fold change Q (%) Function
ALOX12* Arachidonate 12-lipoxygenase 1.7 2.4 1.9 2.1 Arachidonic acid metabolism; 
inflammatory response
BCL6* B-cell CLL/lymphoma 6 1.8 2.4 1.7 1.5 Pleiotropic action in immune response. 
Inhibits B cell apoptosis
CLU Clusterin 1.5 2.4 1.9 2.1 Complement regulatory action
CR1 Complement component (3b/
4b) receptor 1
1.5 2.4 1.9 1.0 Complement receptor, regulates B cell 
apoptosis, immune complex clearance
DEFA4* Defensin, alpha 4, corticostatin 2.1 2.4 4.2 1.2 Non-specific immune response
FAM3B Family with sequence similarity 
3, member B
4.9 2.4 3.6 1.0 IL1-like activity
GRB10* Growth factor receptor-bound 
protein 10
1.8 2.4 1.5 1.0 Regulator of nuclear factor kappa B 
(NFKB)
IL1R1* Interleukin 1 receptor type I 1.6 2.4 2.0 0.4 Binds to IL1
IL1R2* Interleukin 1 receptor, type II 1.6 2.4 1.8 1.5 Decoy target for IL1
MAPK14* Mitogen-activated protein kinase 
14
1.5 2.4 1.6 1.8 Part of the MAPK cascade
NCR3 Natural cytotoxicity triggering 
receptor 3
-2.5 4.9 -1.7 1.5 Required for NK cell-mediated induction of 
dendritic cell maturation
NLRP2/NALP2* NLR family, pyrin domain 
containing 2
-2.5 4.3 -1.7 1.5 Part of the inflammasome; inhibits NFkB. 
Causes caspase-1 activation
PTGS1/COX1 Cyclooxygenase 1 1.9 2.4 1.8 2.1 Prostaglandin synthesis.
SELP Selectin P (CD62) 1.7 2.4 1.6 4.1 Extra-lymphoid T cell recruitment. 
Mediates Endothelial cell and leucocyte 
interaction
SLPI* Secretory leukocyte peptidase 
inhibitor
2.0 2.4 2.4 1.0 Antimicrobial activity; innate host defense 
mechanism
SOD2 Superoxide dismutase 2 1.7 2.4 2.8 1.5 Free radical scavenging enzyme involved 
in defense against oxidative stress
SPARC Secreted protein, acidic, 
cysteine-rich (osteonectin)
3.1 2.4 2.3 0.8 Involved in T cell activity and ossification
THBD* Thrombomodulin 1.5 2.4 1.7 3.1 Innate immune response activity
THBS1 Thrombospondin 1 2.0 2.4 2.0 2.5 Glycoprotein
TREM1 Triggering receptor expressed 
on myeloid cells-like 1
1.9 2.4 2.1 2.5 Amplifies response of NLRP2
Significantly differentially expressed genes with a recognized immune or inflammation-related function present in Set 1 and Set 2. Functional 
annotations were obtained from Online Mendelian Inheritance in Man database [32]. *Secondary analysis indicates that expression level changes 
are more apparent in males.Arthritis Research & Therapy    Vol 11 No 6    Sharma et al.
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exclude a possible effect of gender on the level of transcript
expression. However, as an example, even if the downregula-
tion of NLRP2 is a result of the male predominance in the dis-
ease group, it would nonetheless represent a novel insight into
the male predisposition to SpA.
Discussion
There are few published studies of gene expression in SpA.
Our study reveals a number of genes that are differentially
expressed in peripheral blood of patients with SpA and that
can be related to the current understanding of its pathogene-
sis. Our study differs from prior studies in a variety of method-
ological ways including the number of transcripts studied
(more than 47,000 per subject), the exclusion of patients on
disease-modifying medications, the use of whole blood, which
avoids the potential artifact induced by isolating leukocytes or
leukocyte subsets, and pathway analysis in silico. Use of a pri-
mary dataset and an independent validation dataset provides
additional robustness. Utilizing a false discovery rate calcula-
tion limits the possibility of false positives due to chance alone.
Almost all of the transcripts identified as having increased or
decreased expression [see Additional data file 2] deserve
comment with regard to the pathogenesis of SpA, but space
precludes such a thorough discussion. We have selected a
small number of transcripts for additional comment. The detec-
tion of a set of gene transcripts that may have a role in the
immune response and are differentially expressed in both data-
sets suggests the presence of an 'immune signature' in SpA.
Prior work has strongly implicated the IL-1 family in the patho-
genesis of SpA. Increased IL-1β mRNA has been found in
peripheral blood profiling in individuals with spondyloarthropa-
thy [17]. Genetic studies have found that polymorphisms in
the IL-1 gene family are associated with ankylosing spondylitis
[18] and psoriatic arthritis [19]. The finding that both IL-1
receptor (IL-1R) 1 and IL-1R2 are increased at a transcript
level suggests a possible correlation with a genetic associa-
tion between ERAP1 (ARTS1) polymorphisms and ankylosing
spondylitis [20]; ERAP1 is a proteinase believed to lessen
immune responses by cleaving receptors for cytokines includ-
ing IL-1. Triggering receptor expressed on myeloid cells
(TREM)-1 has also previously been implicated in the patho-
genesis of ankylosing spondylitis [21]. The detection of tran-
scripts that have independently been implicated in SpA adds
to the credibility of gene expression microarray analysis as a
technique to identify causal factors in this disease.
SLPI has not previously been implicated in the pathogenesis
of SpA. SLPI, however, downregulates the synthesis of TNFα
[22] and, as such, may well play an important role in the patho-
genesis of this disease that often responds markedly to TNF
inhibition. SPARC, which is also known as osteonectin, has
been implicated in the pathogenesis of scleroderma [23], but
not SpA. SPARC could logically be listed as a contributor to
bone remodeling (see below), but it also negatively regulates
dendritic cell migration and T cell activation [24].
The reduced expression of Nod-Like receptor family, pyrin
domain containing 2 (NLRP2 or NALP2) is a novel observation
and is especially intriguing. NLRP2 is a component of some
inflammasomes [25] and is a member of the NLR family of pro-
teins many of which function as danger-associated molecular
pattern receptors of the innate immune system. Polymor-
phisms in other NLR and related genes have been implicated
in diseases that share clinical features with SpA, including
Behçet's disease, Crohn's disease, and psoriatic arthritis. Pol-
ymorphisms or mutations in genes encoding components or
regulators of inflammasomes are associated with several
autoinflammatory diseases. NLRP2 functions as an intracellu-
lar pattern recognition receptor whose downstream function
includes activation of caspase 1 and inhibition of nuclear fac-
tor kappa B, both of which lead to regulation of IL-1β (Figure
1) [26,27]. The downregulation of NLRP2 may therefore lead
to upregulation of IL-1β, which in turn may regulate IL-1R
expression [27]. There is no a priori reason to believe that the
expression of a gene such as NLRP2 is affected by gender. If
Table 5
Bone remodeling signature
Set 1 Set 2
Gene symbol Gene name Fold change Q (%) Fold change Q (%) Function
BMP6 Bone morphogenetic protein 6 1.5 2.4 1.7 1.5 Involved in ossification, osteoblast 
differentiation
CTNNAL1* Catenin (cadherin-associated 
protein), alpha-like 1
3 . 02 . 32 . 32 . 1 A n a l o g o u s  t o  α-catenin which inhibits β-
catenin. Á catenin inhibits wnt/catenin 
pathway
KREMEN1 Kringle containing 
transmembrane protein 1
2 . 02 . 42 . 02 . 5 N e g a t i v e  r e g u l a tor of wnt/catenin pathway
PCSK6 Proprotein convertase subtilisin/
kexin type 6
3 . 12 . 42 . 01 . 8 R e g u l a t o r  o f  B M P 6
*Secondary analysis indicates that expression level changes are more apparent in males.Available online http://arthritis-research.com/content/11/6/R168
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NLRP2 is indeed under expressed in males, this downregula-
tion may be an important clue to the male predominance in this
disease.
Ossification is the hallmark of SpA, but there is also ongoing
bone resorption with up to 56% of patients becoming osteo-
penic and a significant proportion becoming osteoporotic
[28]. The wnt-catenin pathway and its primary regulator Dick-
kopf 1 (DKK-1) regulate the balance between osteoblast and
osteoclast function [29]. The upregulation of kremen1 in our
data suggests negative regulation of the wnt-catenin pathway
via its interaction with DKK-1. The net effect of this and other
factors may be bone resorption [30]. Endogenous bone mor-
phogenetic protein 6 (BMP6) has been described in a mouse
model of enthesis ossification and shown to promote osteob-
last differentiation. Inhibition of BMP6 prevents the onset and
progress of an SpA-type model of arthritis [31].
This study has some limitations. Firstly, although the diagnosis
of SpA was made using a validated method, it was not possi-
ble to grade disease activity because most patients were
attending an eye clinic. Patients did not routinely have X-rays
or MRI scans of the pelvis. However, nearly 100% of the
patients had inflammatory lower back pain confirmed by a
rheumatologist. Secondly, the control group consisted of vol-
unteers with females outnumbering males. There was a pre-
dominance of males in the SpA group as is expected in this
condition. Gender differences were apparent for a number of
differentially expressed genes located on sex chromosomes.
These gender-linked genes could be readily identified on the
basis of their chromosomal location and they are not known to
contribute to inflammation [see Additional data file 2]. A post
hoc analysis was conducted on the transcripts selected as
having higher or lower expression levels in SpA subjects to
identify those that were also influenced by gender.
Statistical tests on the effect of gender and/or disease on
gene expression revealed that disease, rather than the dispro-
portionate number of males in the group with SpA, accounted
for the differences in gene expression. However, gender does
play a role in SpA, because the vast majority of patients with
SpA are male. For some transcripts the overexpression or
underexpression of a particular transcript in SpA is more
apparent in males. The directional consistency of differences
revealed by the initial SAM analysis and the secondary analysis
add further support to our findings.
Conclusions
Despite the limitations mentioned above, this study has clearly
identified a number of novel and intriguing potential contribu-
tors to SpA. Gene expression microarray may elucidate patho-
genesis, facilitate diagnostic specificity, correlate with
pharmacologic responsiveness, and predict prognosis. We
based this study in an ophthalmology clinic to test the hypoth-
esis that patients with SpA and active uveitis would express
genes in peripheral blood to distinguish those with uveitis from
those without uveitis. Our initial evaluation of this hypothesis
indicates that a larger database is necessary to determine if
such differences exist. This goal will require large databases
with careful accrual of clinical data. We believe that the
present study represents an important step toward under-
standing the molecular mechanisms of SpA.
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